GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Long-Term Debt & Capital Lease Obligation

Acasti Pharma (Acasti Pharma) Long-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Acasti Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Acasti Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Acasti Pharma's Total Assets for the quarter that ended in Dec. 2023 was $76.19 Mil. Acasti Pharma's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2023 was 0.00.

Acasti Pharma's LT-Debt-to-Total-Asset declined from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that Acasti Pharma is progressively becoming less dependent on debt to grow their business.


Acasti Pharma Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Acasti Pharma's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Long-Term Debt & Capital Lease Obligation Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.07 - 0.19 0.41

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.41 - - -

Acasti Pharma Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Acasti Pharma  (NAS:ACST) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Acasti Pharma's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/76.185
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Acasti Pharma Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (Acasti Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Long-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202

Acasti Pharma (Acasti Pharma) Headlines

From GuruFocus

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

By Stock market mentor Stock market mentor 01-13-2023

Acasti Pharma Inc. Announces the Resignation of a Director

By PRNewswire PRNewswire 03-30-2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

By Stock market mentor Stock market mentor 01-25-2023